TFAM and non-small cell lung carcinoma: A potential explanation for this phenomenon could be increased cisplatin-induced ROS generation in TFAM-knockdown NSCLC cells; conversely, however, ROS levels were reduced by NAC pre-treatment (Figure 3C and 3D; n = 3; *p < 0.05; **p < 0.01; ***p < 0.001).